MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Abstract

Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations. Amivantamab is a bispecific antibody against EGFR and MET alterations. Lazertinib is a tyrosine kinase inhibitor active against EGFR mutations including common resistance mutations. The MARIPOSA trial was designed to study if the combination of amivantamab plus lazertinib in untreated epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients would provide improved progression-free survival. Here, we discuss the rationale for the study and the early results of MARIPOSA.

Keywords:

• epidermal growth factor receptor (EGFR) mutations
• first line treatment
• bispecific antibody

Abbreviations

AUC, area under the concentration–time curve; CI, confidence interval; ctDNA, circulating tumor deoxyribonucleic acid; DCR, disease control rate; DOR, duration of response; EGFR, epidermal growth factor receptor; FDA, Federal Drug Administration; HR, hazard ratio; Kg, kilogram; MET, mesenchymal–epithelial transition factor; Mg, milligrams; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TKI: tyrosine kinase inhibitor.

Data Sharing Statement

Not applicable to this study.

Ethics Approval and Consent to Participate

This report did not meet criteria for IRB approval.

Disclosure

Dr Misako Nagasaka reports personal fees from AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Novartis, EMD Serono, Pfizer, Lilly, Genentech, Regeneron, Takeda, Janssen, Blueprint and Mirati; non-financial support from AnHeart Therapeutics, outside the submitted work. The authors report no other conflicts of interest in this work.

Additional information

Funding

No funding was secured for this report.